Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerHiroyuki Yasuda, Daniel B. Costa, Norihiro Yamaguchi et al.|Science Translational Medicine|2013Cited by 565
Erlotinib as second- or third-line treatment in elderly patients with advanced non-small cell lung cancer: Keio Lung Oncology Group Study 001 (KLOG001)Masayoshi Miyawaki, Kenzo Soejima, Katsuhiko Naoki et al.|Molecular and Clinical Oncology|2017Cited by 10
A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancerKenzo Soejima, Tomoko Betsuyaku, Katsuhiko Naoki et al.|Cancer Chemotherapy and Pharmacology|2015Cited by 7
A phase II trial of induction of erlotinib followed by cytotoxic chemotherapy for EGFR mutation-positive non-squamous non-small cell lung cancer patientsTetsuo Tani, Kenzo Soejima, Katsuhiko Naoki et al.|Cancer Chemotherapy and Pharmacology|2019Cited by 1
Abstract 5652: Activation of FGF2-FGFR1 pathway in EGFR-mutant lung cancer cell line with long-term gefitinib exposure.Hideki Terai, Tomoko Betsuyaku, Kenzo Soejima et al.|Cancer Research|2013Cited by 0